StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)

Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –

Aurinia Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Aurinia Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 90.6%. For fiscal 2025 it was 88.5%, against 88.0% the year before. The highest annual figure on record is 100.0% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202588.5%+0.5
FY2024Dec 31, 202488.0%−4.0
FY2023Dec 31, 202391.9%−3.8
FY2022Dec 31, 202295.8%−1.8
FY2021Dec 31, 202197.6%−2.4
FY2020Dec 31, 2020100.0%+0.0
FY2019Dec 31, 2019100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202690.1%+1.2
Q2 FY2026Jun 30, 202692.1%+2.3
Q1 FY2026Mar 31, 202691.6%+5.4
Q4 FY2025Dec 31, 202588.6%−2.1
Q3 FY2025Sep 30, 202588.9%−2.2
Q2 FY2025Jun 30, 202589.8%+5.4
Q1 FY2025Mar 31, 202586.3%+1.7
Q4 FY2024Dec 31, 202490.7%+2.7
Q3 FY2024Sep 30, 202491.1%+3.5
Q2 FY2024Jun 30, 202484.4%−11.8
Q1 FY2024Mar 31, 202484.6%−14.2
Q4 FY2023Dec 31, 202388.0%−7.2
Q3 FY2023Sep 30, 202387.6%−8.0
Q2 FY2023Jun 30, 202396.2%+1.9
Q1 FY2023Mar 31, 202398.8%−0.0
Q4 FY2022Dec 31, 202295.2%−2.7
Q3 FY2022Sep 30, 202295.6%−2.7
Q2 FY2022Jun 30, 202294.3%−1.0
Q1 FY2022Mar 31, 202298.8%+4.1
Q4 FY2021Dec 31, 202197.9%−2.1
Q3 FY2021Sep 30, 202198.3%−1.7
Q2 FY2021Jun 30, 202195.3%−4.7
Q1 FY2021Mar 31, 202194.7%−5.3
Q4 FY2020Dec 31, 2020100.0%–
Q3 FY2020Sep 30, 2020100.0%–
Q2 FY2020Jun 30, 2020100.0%–
Q1 FY2020Mar 31, 2020100.0%–

More Aurinia Pharmaceuticals figures

See a number that looks wrong?